Quick Answer
RELMADA THERAPEUTICS, INC. reported Net Income of -$57.39 million for fiscal year 2025.
RELMADA THERAPEUTICS, INC. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$57.39M | +28.3% |
| 2024 | -$79.98M | +19.0% |
| 2023 | -$98.79M | +37.1% |
| 2022 | -$157.04M | -24.9% |
| 2021 | -$125.75M | -111.5% |
| 2020 | -$59.46M | -296.2% |
| 2019 | -$15.01M | +13.4% |
| 2019 | -$17.32M | -93.3% |
| 2018 | -$8.96M | -42.5% |
| 2017 | -$6.29M | -111.3% |
| 2016 | -$2.97M | +85.7% |
| 2015 | -$20.80M | -4.7% |
| 2013 | -$19.87M | -44045.1% |
| 2013 | -$45.0K | -273.5% |
| 2012 | -$12.1K | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$10.09M | +53.6% | -2.3% |
| June 30, 2025 | -$9.87M | +44.5% | +43.8% |
| March 31, 2025 | -$17.56M | +19.6% | +19.2% |
| September 30, 2024 | -$21.73M | +1.3% | -22.3% |
| June 30, 2024 | -$17.77M | +29.8% | +18.6% |
| March 31, 2024 | -$21.83M | +17.1% | +0.8% |
| September 30, 2023 | -$22.00M | +44.2% | +13.0% |
| June 30, 2023 | -$25.30M | +36.6% | +3.9% |
- RELMADA THERAPEUTICS, INC. showed an increase of +28.3% in Net Income compared to the prior fiscal year.
- Over the 2012–2025 period, RELMADA THERAPEUTICS, INC.’s net income has declined by 476046.4% (from -$12.1 thousand to -$57.39 million).
- The most recent figure is from RELMADA THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: